82F logo

NFL Biosciences SADB:82F Stock Report

Market Cap €10.5m
Share Price
n/a
1Y-31.6%
7D-1.7%
1D-0.9%
Portfolio Value
​
View

NFL Biosciences SA

DB:82F Stock Report

Market Cap: €10.5m

NFL Biosciences (82F) Stock Overview

A biotechnology company, engages in the development of botanical drugs in France. More details

82F fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Earnings have declined by 21.8% per year over past 5 years

Makes less than USD$1m in revenue (€188)

Does not have a meaningful market cap (€11M)


82F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW479,582 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
479,582 investors already sharing narratives
View all narratives

NFL Biosciences SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for NFL Biosciences
Historical stock prices
Current Share Price€0.75
52 Week High€1.61
52 Week Low€0.73
Beta1.15
1 Month Change3.01%
3 Month Change-21.05%
1 Year Change-31.58%
3 Year Change-69.72%
5 Year Change-77.08%
Change since IPO-76.44%

Recent News & Updates

Recent updates

Shareholder Returns

82FDE BiotechsDE Market
7D-1.7%-0.1%0.1%
1Y-31.6%11.4%-0.5%

Return vs Industry: 82F underperformed the German Biotechs industry which returned 13.3% over the past year.

Return vs Market: 82F underperformed the German Market which returned 0.3% over the past year.

Price Volatility

Is 82F's price volatile compared to industry and market?
82F volatility
82F Average Weekly Movement15.4%
Biotechs Industry Average Movement7.7%
Market Average Movement5.3%
10% most volatile stocks in DE Market12.7%
10% least volatile stocks in DE Market2.7%

Stable Share Price: 82F's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 82F's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20064Bruno Lafontwww.nflbiosciences.com

NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation.

NFL Biosciences SA Fundamentals Summary

How do NFL Biosciences's earnings and revenue compare to its market cap?
82F fundamental statistics
Market cap€10.52m
Earnings (TTM)-€3.32m
Revenue (TTM)€188.00
Over9,999x
P/S Ratio
-3.2x
P/E Ratio

Is 82F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
82F income statement (TTM)
Revenue€188.00
Cost of Revenue€2.52m
Gross Profit-€2.52m
Other Expenses€799.27k
Earnings-€3.32m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Oct 22, 2026

Earnings per share (EPS)-0.26
Gross Margin-1,339,733.51%
Net Profit Margin-1,764,876.06%
Debt/Equity Ratio142.1%

How did 82F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/22 20:37
End of Day Share Price 2026/07/22 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NFL Biosciences SA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Clément BassatPortzamparc BNP Paribas